N-acetylcysteine reduces oxidative stress, nuclear factor-κB activity and cardiomyocyte apoptosis in heart failure

Molecular Medicine Reports

Volumn 10, Issue 2, 2014, Pages 615-624

  Wu, Xiao Yan ^a   Luo, An Yu ^b   Zhou, Yi Rong ^c   Ren, Jiang Hua ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Heart failure; N acetylcysteine; Nuclear factor B; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; 8-EPI-PROSTAGLANDIN F2ALPHA; GLUTATHIONE; I KAPPA B; NF-KAPPAB INHIBITOR ALPHA; PROSTAGLANDIN F2 ALPHA; PROTEIN BAX; PROTEIN BCL 2; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CELL; HEMODYNAMICS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RABBIT; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; HEART MUSCLE; METABOLISM; PATHOLOGY;

ACETYLCYSTEINE; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; DINOPROST; DISEASE MODELS, ANIMAL; GLUTATHIONE; HEART FAILURE; HEMODYNAMICS; I-KAPPA B PROTEINS; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-BCL-2; RABBITS; TRANSCRIPTION FACTOR RELA;

EID: 84903310262     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2292     Document Type: Article

References (50)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al: Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 121: e46-e215, 2010.
2. Roger VL, Go AS, Lloyd-Jones DM, et al: Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 125: e2-e220, 2012.
3. Owan TE and Redfield MM: Epidemiology of diastolic heart failure. Progr Cardiovasc Dis 47: 320-332, 2005. (Pubitemid 40884561)
4. Ellis ER and Josephson ME: Heart failure and tachycardia-induced cardiomyopathy. Curr Heart Fail Rep 10: 296-306, 2013.
5. Yancy CW: Heart failure in African Americans. Am J Cardiol 96: 3i-12i, 2005.
6. Thomas KL, Piccini JP, Liang L, et al: Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure. J Am Heart Assoc 2: e000200, 2013.
7. Neubauer S: The failing heart-an engine out of fuel. N Engl J Med 356: 1140-1151, 2007.
8. Giordano FJ: Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115: 500-508, 2005.
9. White M, Ducharme A, Ibrahim R, et al: Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. Clin Sci (Lond) 110: 483-489, 2006.
10. Hare JM: Oxidative stress and apoptosis in heart failure progression. Circ Res 89: 198-200, 2001.
11. Sawyer DB, Siwik DA, Xiao L, et al: Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 34: 379-388, 2002. (Pubitemid 37163454)
12. Abbate A, Bussani R, Amin MS, Vetroec GW, et al: Acute myocardial infarction and heart failure: role of apoptosis. Int J Biochem Cell Biol 38: 1834-1840, 2006. (Pubitemid 44425247)
13. Wang RP, Yao Q, Xiao YB, et al: Toll-like receptor 4/nuclear factor-kappa B pathway is involved in myocardial injury in a rat chronic stress model. Stress 14: 567-575, 2011.
14. Gordon JW, Shaw JA and Kirshenbaum LA: Multiple facets of NF-κB in the heart: to be or not to NF-κB. Circ Res 108: 1122-1132, 2011.
15. Frantz S, Hu K, Bayer B, et al: Absence of NF-kappaB subunit p50 improves heart failure after myocardial infarction. FASEB 20: 1918-1920, 2006.
16. Galang N, Sasaki H and Maulik N: Apoptotic cell death during ischemia/reperfusion and its attenuation by antioxidant therapy. Toxicology 148: 111-118, 2000. (Pubitemid 30621350)
17. Jones SM, Kirby MS, Harding SE, et al: Adriamycin cardiomyopathy in the rabbit: alterations in contractile proteins and myocyte function. Cardiovasc Res 24: 834-842, 1990. (Pubitemid 20331488)
18. Andre L, Fauconnier J, Reboul C, et al: Subendocardial increase in reactive oxygen species production affects regional contractile function in ischemic heart failure. Antioxid Redox Signal 18: 1009-1020, 2013.
19. van Dalen EC, Caron HN, Dickinson HO, et al: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 15: CD003917, 2011.
20. Carvalho FS, Burgeiro A, Garcia R, et al: Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev 34: 106-135, 2014.
21. Dolinsky VW, Rogan KJ, Sung MM, et al: Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. Am J Physiol Endocrinol Metab 305: E243-E253, 2013.
22. Langton D, Jover B, McGrath BP, et al: Cardiovascular responses to graded treadmill exercise during the development of doxorubicin induced heart failure in rabbits. Cardiovasc Res 24: 959-968, 1990.
23. Sarandol A, Sarandol E, Eker SS, et al: Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 22: 67-73, 2007. (Pubitemid 46505714)
24. Erel O: A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 37: 112-119, 2004.
25. Ye J, Ding M, Zhang X, et al: On the role of hydroxyl radical and the effect of tetrandrine on nuclear factor-κB activation by phorbol 12-myristate 13-acetate. Ann Clin Lab Sci 30: 65-71, 2000. (Pubitemid 30078306)
26. Kone BC, Schwöbel J, Turner P, et al: Role of NF-kappa B in the regulation of inducible nitric oxide synthase in an MTAL cell line. Am J Physiol 269: F718-F729, 1995. (Pubitemid 3006022)
27. Kubin AM, Skoumal R, Tavi P, et al: Role of reactive oxygen species in the regulation of cardiac contractility. J Mol Cell Cardiol 50: 884-893, 2011.
28. Finn NA and Kemp ML: Pro-oxidant and antioxidant effects of N-acetylcysteine regulate doxorubicin-induced NF-kappa B activity in leukemic cells. Mol Biosyst 8: 650-662, 2012.
29. Sagristá ML, García AE, Africa De Madariaga M, et al: Antioxidant and pro-oxidant effect of the thiolic compounds N-acetyl-L-cysteine and glutathione against free radical-induced lipid peroxidation. Free Radic Res 36: 329-340, 2002. (Pubitemid 35154078)
30. The Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th edition. Little, Brown & Co. Boston, pp253-256, 1994.
31. You JS, Huang HF and Chang YL: Panax ginseng reduces adriamycin-induced heart failure in rats. Phytother Res 19: 1018-1022, 2005.
32. Dong JW, Zhu HF, Zhu WZ, et al: Intermittent hypoxia attenuates ischemia/reperfusion induced apoptosis in cardiac myocytes via regulating Bcl-2/Bax expression. Cell Res 13: 385-391, 2003.
33. Sabbah HN, Sharov VG, Gupata RC, et al: Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. J Am Coll Cardiol 36: 1698-1705, 2000.
34. Burke JR: Targeting I kappa B kinase for the treatment of inflammatory and other disorders. Curr Opin Drug Discov Devel 6: 720-728, 2003.
35. Squadrito F, Deodato B, Squadrito G, et al: Gene transfer of IkappaBalpha limit infarct ischemia-reperfusion injury. Lab Invest 83: 1097-1104, 2003.
36. Altavilla D, Deodato B, Campo GM, et al: IRFI 042, a novel dual vitamin E-like antioxidant, inhibits activation of nuclear factor-kappaB and reduces the inflammatory response in myocardial ischemia-reperfusion injury. Cardiovasc Res 47: 515-528, 2000. (Pubitemid 30646073)
37. Monaco C and Paleolog E: Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 61: 671-682, 2004. (Pubitemid 38249466)
38. Maier HJ, Schips TG, Wietelmann A, et al: Cardiomyocyte-specific IκB kinase (IKK)/NF-κB activation induces reversible inflammatory cardiomyopathy and heart failure. Proc Natl Acad Sci USA 109: 11794-11799, 2012.
39. Hall G, Hasday JD and Rogers TB: Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol 41: 580-591, 2006. (Pubitemid 44374539)
40. Pye J, Ardeshirpour F, McCain A, et al: Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 284: H919-H926, 2003. (Pubitemid 36228240)
41. Gao Y, Lecker S, Post MJ, et al: Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Invest 106: 439-448, 2000. (Pubitemid 30655644)
42. Inserte J, Taimor G, Hofstaetter B, et al: Influence of simulated ischemia on apoptosis induction by oxidative stress in adult cardiomyocytes of rat. Am J Physiol Heart Circ Physiol 278: H94-H99, 2000. (Pubitemid 30101860)
43. Crespo MJ, Cruz N, Altieri PI, et al: Chronic treatment with N-acetylcysteine improves cardiac function but does not prevent progression of cardiomyopathy in Syrian cardiomyopathic hamsters. J Cardiovasc Pharmacol Ther 16: 197-204, 2011.
44. Haleagrahara N, Julian V and Chakravarthi S: N-acetylcysteine offers cardioprotection by decreasing cardiac lipid hydroperoxides and 8-isoprostane level in isoproterenol-induced cardiotoxicity in rats. Cardiovasc Toxicol 11: 373-381, 2011.
45. Basha RH and Priscilla DH: An in vivo and in vitro study on the protective effects of N-acetylcysteine on mitochondrial dysfunction in isoproterenol treated myocardial infarcted rats. Exp Toxicol Pathol 65: 7-14, 2013.
46. Adamy C, Le Corvoisier P, Candiani G, et al: Tumor necrosis factor alpha and glutathione interplay in chronic heart failure. Arch Mal Coeur Vaiss 98: 906-912, 2005.
47. Chen F, Hadfield JM, Berzingi C, et al: N-acetylcysteine reverses cardiac myocyte dysfunction in a rodent model of behavioral stress. J Appl Physiol (1985) 115: 514-524, 2013.
48. Wang T, Qiao S, Lei S, et al: N-acetylcysteine and allopurinol synergistically enhance cardiac adiponectin content and reduce myocardial reperfusion injury in diabetic rats. PLoS One 6: e23967, 2011.
49. Dresdale AR, Barr LH, Bonow RO, et al: Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy. Am J Clin Oncol 5: 657-663, 1982. (Pubitemid 13149997)
50. Jo SH, Kim LS, Kim SA, et al: Evaluation of short-term use of N-acetylcysteine as a strategy for prevention of anthracycline-induced cardiomyopathy: EPOCH trial-a prospective randomized study. Korean Circ J 43: 174-181, 2013.